research article review on bevacizumab production

 Bevacizumab is a recombinant humanized monoclonal antibody that targets the vascular endothelial growth factor (VEGF) protein. It is used to treat a variety of cancers, such as colorectal, lung, glioblastoma, and renal cell carcinomas. Bevacizumab was first approved by the US Food and Drug Administration (FDA) in 2004 for the treatment of metastatic colon and lung cancer.

The development of bevacizumab began in the late 1990s, when scientists at Genentech, a subsidiary of Roche, recognized the potential of targeting VEGF for the treatment of cancer. The VEGF protein is known to promote the growth of new blood vessels, which is essential for the growth and spread of tumors. By targeting VEGF, bevacizumab can inhibit the growth of new blood vessels and thus, slow the growth of tumors.

To develop bevacizumab, Genentech scientists first identified a mouse monoclonal antibody that binds to VEGF, and then humanized it to minimize the potential for an immune response. The humanized antibody was then expressed in Chinese hamster ovary (CHO) cells using recombinant DNA technology.

The development of bevacizumab also required extensive preclinical and clinical testing to determine its safety and efficacy. In phase I and II clinical trials, bevacizumab was shown to be well-tolerated and to have anti-tumor activity in patients with various types of cancer. In phase III clinical trials, bevacizumab was shown to significantly improve the progression-free survival and overall survival of patients with metastatic colon and lung cancer when given in combination with standard chemotherapy.

In conclusion, the development of bevacizumab required a combination of basic research, protein engineering, recombinant DNA technology, and extensive preclinical and clinical testing. The drug was able to inhibit the growth of new blood vessels and slow the growth of tumors, which made it effective in treating a variety of cancers. Bevacizumab is now widely used as a targeted therapy in oncology, and it has been approved for the treatment of multiple types of cancer.

Comments

Post a Comment

Popular posts from this blog

MOA OF AMINOGLYCOSIDE ANTIBIOTICS

Image
MOA                  of   Aminoglycoside             Antibiotics Aminoglycosides exert their bactericidal effect by inhibiting protein synthesis in bacteria and compromising the structure of the bacterial cell wall . Aminoglycoside Antibiotics Aminoglycoside antibiotics are used to treat serious infections caused by gram-negative bacteria . Some commonly used aminoglycosides include: amikacin (Amikin®); apramycin; capreomycin; gentamicin (Garamycin®); kanamycin (Kantrex®); neomycin (Mycifradin®); netilmicin (Netromycin®); paromomycin (Humatin®); streptomycin; tobramycin (TOBI Solution®, TobraDex®, Nebcin®) Mode of Action Although aminoglycosides stop bacteria from making proteins, it is uncertain whether this is the action that results in bacterial cell death.     Disruption of Protein Synthesis A minoglyco s i d e s b i n d to the b a c t er i al 3 0 S r i b o s o mal s ubunit. R i b o s om e s are the p ro t e i n
Read more

article review on adalimumab production

Adalimumab is a recombinant human monoclonal antibody that is used to treat a variety of inflammatory diseases, such as rheumatoid arthritis, psoriasis, and Crohn's disease. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. A research article "Development of a high-titer, high-density fed-batch process for the production of adalimumab in CHO cells" by Chen et al. (2018) aimed to improve the production of adalimumab by developing a high-titer and high-density fed-batch process. The study used a CHO cell line that had been modified to express the adalimumab gene. The cells were grown in a culture medium containing glucose, amino acids, and a proprietary feed supplement, and the culture conditions were optimized to achieve high yields of the protein. The results of the study showed that a high yield of adalimumab (over 2g/L) was achieved using the fed-batch cultivation system. The study also found that the specific productivity of th
Read more

Why 70% Isopropyl Alcohol (IPA) is used as Disinfectant in Pharmaceuticals?

Image
  Why 70% Isopropyl Alcohol (IPA) is used as Disinfectant in Pharmaceuticals? Know why 70% isopropyl alcohol ( IPA solution ) is used for disinfection of hands and equipment surface instead of 100% in pharmaceuticals. 70% isopropyl alcohol is most commonly used disinfectant in pharmaceutical industries. The important thing is that only 70% solution of isopropyl alcohol acts as a disinfectant killing all surface microorganisms. It is used to disinfect hands and equipment surface in pharmaceuticals. 70 % isopropyl alcohol solution kills microorganisms by dissolving plasma membrane of the cell wall. The plasma membrane of gram-negative bacteria consists of thin layer of peptidoglycan that easily destroyed by the alcohol. Therefore, 70 percent isopropyl alcohol is known as pharmaceutical alcohol. Water is also required to denature the proteins of the cell membrane and acts as a catalyst for the reaction. The contact time of the alcohol with the organism also plays an important role. A 70%
Read more